Analysts Expect JHSC To Hit $45

Analysts project a 15.51% upside for the John Hancock Multifactor Small Cap ETF (JHSC), with an implied target price of $44.75 based on underlying holdings, compared to its recent price of $38.74. Within JHSC, CRISPR Therapeutics AG (CRSP), LIBERTY GLOBAL LTD C (LBTYK), and Core Scientific Inc (CORZ) show the most significant potential upside, with analyst target prices suggesting gains of 90.48%, 62.77%, and 43.83% respectively; however, investors should consider whether these targets are justified given recent company and industry developments.

Analysis

The John Hancock Multifactor Small Cap ETF (JHSC) demonstrates a potential 15.51% upside, with an implied analyst target price of $44.75 per unit compared to its recent trading price of $38.74. This projected appreciation is substantially driven by certain underlying holdings, particularly CRISPR Therapeutics AG (CRSP), which has an average analyst target price of $80.17, representing a 90.48% increase from its recent price of $42.09. Similarly, LIBERTY GLOBAL LTD C (LBTYK) shows a 62.77% potential upside with a target of $16.00 from its recent $9.83, and Core Scientific Inc (CORZ) is projected to reach $18.28, a 43.83% increase from its $12.71 price. While these analyst targets indicate significant optimism, particularly for these specific small-cap stocks, the article appropriately raises questions about the validity of these projections, urging investors to ascertain whether these targets are well-founded or potentially overly optimistic relics of past assessments, necessitating further research into underlying company and industry developments. The overall sentiment conveyed is moderately positive, with a speculative tone regarding the future performance of these assets.

Key Decisions for Investors

• Investors may consider the John Hancock Multifactor Small Cap ETF (JHSC) for diversified exposure to small-cap stocks, given the weighted average implied analyst upside of 15.51%.